Edgar Filing: Labrucherie Gil M - Form 4

Labrucherie Gil Form 4	Μ											
December 19, 20)17											
FORM 4										OMB APPROVAL		
	Washington, D.C. 20549						COMMISSION	OMB Number:	3235-0287			
Check this bo if no longer subject to Section 16. Form 4 or Form 5 obligations	STATEM Filed pure	Section 17(a) of the Public Utility Holding Company Act of 1935 or Section							Expires: January 31, 2005 Estimated average burden hours per response 0.5			
may continue. <i>See</i> Instruction 1(b).	•		of the Inv	-		-				11		
(Print or Type Respo	onses)											
1. Name and Address of Reporting Person <u>*</u> Labrucherie Gil M			2. Issuer Name and Ticker or Trading Symbol NEKTAR THERAPEUTICS					g	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last)	(First) (M	First) (Middle) 3. Date of Earliest T			Гraı	nsaction			Director 10% Owner X Officer (give title Other (specify			
C/O NEKTAR THERAPEUTIC BAY BOULEV			(Month/Da 12/15/20						below)	below) hief Financial O		
	(Street)		If Amendment, Date Original ed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
SAN FRANCIS	CO, CA 9415	58							Form filed by N Person	Iore than One Re	porting	
(City)	(State)	(Zip)	Table	e I - Non-	De	rivative S	ecurit	ies Acq	uired, Disposed of	f, or Beneficial	ly Owned	
	Transaction Date lonth/Day/Year)	Executio any		3. Transac Code (Instr. 8 Code	tior)	4. Securit n(A) or Dis (D) (Instr. 3, 4 Amount	sposed	of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
$\frac{\text{Common}}{\text{Stock } \underline{(1)}} \qquad 12$	2/15/2017			А		26,000	А	\$0	103,216 <u>(2)</u>	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

ree copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
sons who are to respond to the collection of information contained in this form are not required to respond unless the form displa

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

Reporting Owner Name / Address

455 MISSION BAY BOULEVARD SOUTH

Explanation of Responses:

Labrucherie Gil M

Signatures Mark A. Wilson,

Attorney-in-Fact

**

C/O NEKTAR THERAPEUTICS

SAN FRANCISCO, CA 94158

**Signature of Reporting Person

This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, (1) upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly

12/19/2017

Date

This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 3,750 shares held by the reporting person in

Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- installments based on continued service.
- (2) the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).

Director

(3) This stock option vests over four years in equal monthly installments based on continued service.

Note: File three Potential perso lays a currently valid OMB number.

Edgar Filing: Labrucherie Gil M - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date 3A. Deemed (Month/Day/Year) Execution Date, if any (Month/Day/Year)		4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 D S (1	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		
Stock Option	\$ 56.9	12/15/2017		А	65,000	(3)	12/14/2025	Common Stock	65,000		
Reporting Owners											

10% Owner

Relationships

SVP & Chief Financial Officer

Other

Officer